Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.06 USD
-0.09 (-0.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $24.97 -0.09 (-0.36%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.06 USD
-0.09 (-0.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $24.97 -0.09 (-0.36%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Anika Therapeutics (ANIK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Anika Therapeutics (ANIK) closed the most recent trading day at $30.07, moving -1.92% from the previous trading session.
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
by Zacks Equity Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
Anika Therapeutics (ANIK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of -20.83% and 10.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 23.08% and 8.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review
by Zacks Equity Research
The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
by Zacks Equity Research
Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.
Techne (TECH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 7% and 2.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 26th
by Zacks Equity Research
ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
New Strong Sell Stocks for April 19th
by Zacks Equity Research
ANIK, APP, and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2022.
New Strong Sell Stocks for April 7th
by Zacks Equity Research
AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
New Strong Sell Stocks for April 4th
by Zacks Equity Research
AKU, ANIK, and AY have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2022.
New Strong Sell Stocks for March 28th
by Zacks Equity Research
ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022
New Strong Sell Stocks for March 21st
by Zacks Equity Research
ARAY, AKU, and ANIK have been added to the Zacks Rank #5 (Strong Sell) List on March 21, 2022
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.02% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -423.08% and 81.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 144.44% and 8.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Anika Therapeutics (ANIK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika Therapeutics (ANIK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 225.00% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?